# A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer

> **NCT00121628** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 184 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** AMG 706

## Key facts

- **NCT ID:** NCT00121628
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2006-11
- **Final completion:** 2010-10
- **Target enrollment:** 184 (ACTUAL)
- **Last updated:** 2013-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00121628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00121628, "A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00121628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*